ID   ANPRB_HUMAN             Reviewed;        1047 AA.
AC   P20594; B0ZBF2; B0ZBF3; D3DRP3; D3DRP4; O60871; Q4VAK7; Q5TCV2;
AC   Q8TA93; Q9UQ50;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1991, sequence version 1.
DT   10-MAY-2017, entry version 192.
DE   RecName: Full=Atrial natriuretic peptide receptor 2;
DE            EC=4.6.1.2 {ECO:0000269|PubMed:26980729};
DE   AltName: Full=Atrial natriuretic peptide receptor type B;
DE            Short=ANP-B;
DE            Short=ANPR-B;
DE            Short=NPR-B;
DE   AltName: Full=Guanylate cyclase B;
DE            Short=GC-B;
DE   Flags: Precursor;
GN   Name=NPR2; Synonyms=ANPRB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE (ISOFORM LONG).
RC   TISSUE=Brain;
RX   PubMed=2570358; DOI=10.1038/341068a0;
RA   Chang M.S., Lowe D.G., Lewis M., Hellmiss R., Chen E., Goeddel D.V.;
RT   "Differential activation by atrial and brain natriuretic peptides of
RT   two different receptor guanylate cyclases.";
RL   Nature 341:68-72(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RX   PubMed=10082481; DOI=10.1161/01.RES.84.5.605;
RA   Rehemudula D., Nakayama T., Soma M., Takahashi Y., Uwabo J., Sato M.,
RA   Izumi Y., Kanmatsuse K., Ozawa Y.;
RT   "Structure of the type B human natriuretic peptide receptor gene and
RT   association of a novel microsatellite polymorphism with essential
RT   hypertension.";
RL   Circ. Res. 84:605-610(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT).
RC   TISSUE=Kidney;
RX   PubMed=10073597;
RA   Hirsch J.R., Meyer M., Maegert H.-J., Forssmann W.-G., Mollerup S.,
RA   Herter P., Weber G., Cermak R., Ankorina-Stark I., Schlatter E.,
RA   Kruhoffer M.;
RT   "cGMP-dependent and -independent inhibition of a K+ conductance by
RT   natriuretic peptides: molecular and functional studies in human
RT   proximal tubule cells.";
RL   J. Am. Soc. Nephrol. 10:472-480(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   LIGAND-BINDING.
RX   PubMed=1660465;
RA   Bennett B.D., Bennett G.L., Vitangcol R.V., Jewett J.R., Burnier J.,
RA   Henzel W., Lowe D.G.;
RT   "Extracellular domain-IgG fusion proteins for three human natriuretic
RT   peptide receptors. Hormone pharmacology and application to solid phase
RT   screening of synthetic peptide antisera.";
RL   J. Biol. Chem. 266:23060-23067(1991).
RN   [9]
RP   FUNCTION.
RX   PubMed=1672777; DOI=10.1126/science.1672777;
RA   Koller K.J., Lowe D.G., Bennett G.L., Minamino N., Kangawa K.,
RA   Matsuo H., Goeddel D.V.;
RT   "Selective activation of the B natriuretic peptide receptor by C-type
RT   natriuretic peptide (CNP).";
RL   Science 252:120-123(1991).
RN   [10]
RP   SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S).
RX   PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8;
RA   Hillman R.T., Green R.E., Brenner S.E.;
RT   "An unappreciated role for RNA surveillance.";
RL   Genome Biol. 5:R8.1-R8.16(2004).
RN   [11]
RP   FUNCTION, VARIANTS AMDM THR-32; GLY-115; GLU-176; MET-297; CYS-338;
RP   THR-409; GLU-413; CYS-708; TRP-776; CYS-957 AND ALA-959, AND
RP   CHARACTERIZATION OF VARIANTS AMDM GLY-115; MET-297 AND GLU-413.
RX   PubMed=15146390; DOI=10.1086/422013;
RA   Bartels C.F., Buekuelmez H., Padayatti P., Rhee D.K.,
RA   van Ravenswaaij-Arts C., Pauli R.M., Mundlos S., Chitayat D.,
RA   Shih L.-Y., Al-Gazali L.I., Kant S., Cole T., Morton J.,
RA   Cormier-Daire V., Faivre L., Lees M., Kirk J., Mortier G.R., Leroy J.,
RA   Zabel B., Kim C.A., Crow Y., Braverman N.E., van den Akker F.,
RA   Warman M.L.;
RT   "Mutations in the transmembrane natriuretic peptide receptor NPR-B
RT   impair skeletal growth and cause acromesomelic dysplasia, type
RT   Maroteaux.";
RL   Am. J. Hum. Genet. 75:27-34(2004).
RN   [12]
RP   PHOSPHORYLATION AT SER-513; THR-516; SER-518; SER-523; SER-526 AND
RP   THR-529.
RX   PubMed=20977274; DOI=10.1021/bi101700e;
RA   Yoder A.R., Stone M.D., Griffin T.J., Potter L.R.;
RT   "Mass spectrometric identification of phosphorylation sites in
RT   guanylyl cyclase A and B.";
RL   Biochemistry 49:10137-10145(2010).
RN   [13]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-232 AND ILE-882.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [14]
RP   INVOLVEMENT IN ECDM, VARIANT ECDM MET-882, AND CHARACTERIZATION OF
RP   VARIANT ECDM MET-882.
RX   PubMed=22870295; DOI=10.1371/journal.pone.0042180;
RA   Miura K., Namba N., Fujiwara M., Ohata Y., Ishida H., Kitaoka T.,
RA   Kubota T., Hirai H., Higuchi C., Tsumaki N., Yoshikawa H., Sakai N.,
RA   Michigami T., Ozono K.;
RT   "An overgrowth disorder associated with excessive production of cGMP
RT   due to a gain-of-function mutation of the natriuretic peptide receptor
RT   2 gene.";
RL   PLoS ONE 7:E42180-E42180(2012).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, INVOLVEMENT IN SNSK, VARIANTS SNSK
RP   PRO-76; PRO-263 AND CYS-819, AND CHARACTERIZATION OF VARIANTS SNSK
RP   PRO-76; PRO-263 AND CYS-819.
RX   PubMed=24001744; DOI=10.1210/jc.2013-2142;
RA   Vasques G.A., Amano N., Docko A.J., Funari M.F., Quedas E.P.,
RA   Nishi M.Y., Arnhold I.J., Hasegawa T., Jorge A.A.;
RT   "Heterozygous mutations in natriuretic peptide receptor-B (NPR2) gene
RT   as a cause of short stature in patients initially classified as
RT   idiopathic short stature.";
RL   J. Clin. Endocrinol. Metab. 98:E1636-E1644(2013).
RN   [16]
RP   FUNCTION, SUBCELLULAR LOCATION, INVOLVEMENT IN SNSK, VARIANTS SNSK
RP   CYS-110 AND GLU-417, VARIANT ILE-187, CHARACTERIZATION OF VARIANTS
RP   SNSK CYS-110 AND GLU-417, AND CHARACTERIZATION OF VARIANT ILE-187.
RX   PubMed=24471569; DOI=10.1210/jc.2013-3525;
RA   Amano N., Mukai T., Ito Y., Narumi S., Tanaka T., Yokoya S., Ogata T.,
RA   Hasegawa T.;
RT   "Identification and functional characterization of two novel NPR2
RT   mutations in Japanese patients with short stature.";
RL   J. Clin. Endocrinol. Metab. 99:E713-E718(2014).
RN   [17]
RP   CHARACTERIZATION OF VARIANT ECDM MET-882.
RX   PubMed=23827346; DOI=10.1016/j.bone.2013.06.024;
RA   Robinson J.W., Dickey D.M., Miura K., Michigami T., Ozono K.,
RA   Potter L.R.;
RT   "A human skeletal overgrowth mutation increases maximal velocity and
RT   blocks desensitization of guanylyl cyclase-B.";
RL   Bone 56:375-382(2013).
RN   [18]
RP   CHARACTERIZATION OF VARIANTS AMDM PHE-658; CYS-708; TRP-776 AND
RP   ALA-959, FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, TOPOLOGY,
RP   GLYCOSYLATION, PHOSPHORYLATION, AND MUTAGENESIS OF ASN-24.
RX   PubMed=26980729; DOI=10.1074/jbc.M115.704015;
RA   Dickey D.M., Edmund A.B., Otto N.M., Chaffee T.S., Robinson J.W.,
RA   Potter L.R.;
RT   "Catalytically active guanylyl cyclase b requires endoplasmic
RT   reticulum-mediated glycosylation, and mutations that inhibit this
RT   process cause dwarfism.";
RL   J. Biol. Chem. 291:11385-11393(2016).
RN   [19]
RP   VARIANT AMDM PHE-658, AND CHARACTERIZATION OF VARIANT AMDM PHE-658.
RX   PubMed=17652215; DOI=10.1210/jc.2007-1101;
RA   Hachiya R., Ohashi Y., Kamei Y., Suganami T., Mochizuki H., Mitsui N.,
RA   Saitoh M., Sakuragi M., Nishimura G., Ohashi H., Hasegawa T.,
RA   Ogawa Y.;
RT   "Intact kinase homology domain of natriuretic peptide receptor-B is
RT   essential for skeletal development.";
RL   J. Clin. Endocrinol. Metab. 92:4009-4014(2007).
RN   [20]
RP   VARIANT ECDM CYS-655, AND CHARACTERIZATION OF VARIANT ECDM CYS-655.
RX   PubMed=24057292; DOI=10.1210/jc.2013-2358;
RA   Hannema S.E., van Duyvenvoorde H.A., Premsler T., Yang R.B.,
RA   Mueller T.D., Gassner B., Oberwinkler H., Roelfsema F., Santen G.W.,
RA   Prickett T., Kant S.G., Verkerk A.J., Uitterlinden A.G., Espiner E.,
RA   Ruivenkamp C.A., Oostdijk W., Pereira A.M., Losekoot M., Kuhn M.,
RA   Wit J.M.;
RT   "An activating mutation in the kinase homology domain of the
RT   natriuretic peptide receptor-2 causes extremely tall stature without
RT   skeletal deformities.";
RL   J. Clin. Endocrinol. Metab. 98:E1988-E1998(2013).
RN   [21]
RP   VARIANT ECDM PRO-488, AND CHARACTERIZATION OF VARIANT ECDM PRO-488.
RX   PubMed=24259409; DOI=10.1002/ajmg.a.36218;
RA   Miura K., Kim O.H., Lee H.R., Namba N., Michigami T., Yoo W.J.,
RA   Choi I.H., Ozono K., Cho T.J.;
RT   "Overgrowth syndrome associated with a gain-of-function mutation of
RT   the natriuretic peptide receptor 2 (NPR2) gene.";
RL   Am. J. Med. Genet. A 164A:156-163(2014).
CC   -!- FUNCTION: Receptor for the C-type natriuretic peptide NPPC/CNP
CC       hormone. Has guanylate cyclase activity upon binding of its
CC       ligand. May play a role in the regulation of skeletal growth.
CC       {ECO:0000269|PubMed:15146390, ECO:0000269|PubMed:1672777,
CC       ECO:0000269|PubMed:24001744, ECO:0000269|PubMed:24471569,
CC       ECO:0000269|PubMed:26980729}.
CC   -!- CATALYTIC ACTIVITY: GTP = 3',5'-cyclic GMP + diphosphate.
CC       {ECO:0000269|PubMed:26980729}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:24001744,
CC       ECO:0000269|PubMed:26980729}; Single-pass type I membrane protein
CC       {ECO:0000305|PubMed:26980729}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long;
CC         IsoId=P20594-1; Sequence=Displayed;
CC       Name=Short; Synonyms=NPR-BI;
CC         IsoId=P20594-2; Sequence=VSP_001810;
CC         Note=May be produced at very low levels due to a premature stop
CC         codon in the mRNA, leading to nonsense-mediated mRNA decay.;
CC   -!- PTM: Phosphorylated (PubMed:26980729). Phosphorylation of the
CC       protein kinase-like domain is required for full activation by CNP
CC       (By similarity). {ECO:0000250|UniProtKB:P16067,
CC       ECO:0000269|PubMed:26980729}.
CC   -!- PTM: Glycosylated. {ECO:0000269|PubMed:26980729}.
CC   -!- DISEASE: Acromesomelic dysplasia, Maroteaux type (AMDM)
CC       [MIM:602875]: An autosomal recessive acromesomelic
CC       chondrodysplasia. Acromesomelic chondrodysplasias are rare
CC       hereditary skeletal disorders characterized by short stature, very
CC       short limbs and hand/foot malformations. The severity of limb
CC       abnormalities increases from proximal to distal with profoundly
CC       affected hands and feet showing brachydactyly and/or rudimentary
CC       fingers (knob-like fingers). AMDM is characterized by axial
CC       skeletal involvement with wedging of vertebral bodies. In AMDM all
CC       skeletal elements are present but show abnormal rates of linear
CC       growth. {ECO:0000269|PubMed:15146390, ECO:0000269|PubMed:17652215,
CC       ECO:0000269|PubMed:26980729}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Epiphyseal chondrodysplasia, Miura type (ECDM)
CC       [MIM:615923]: An overgrowth syndrome characterized by tall
CC       stature, long hands and feet with arachnodactyly, macrodactyly of
CC       the great toes, scoliosis, coxa valga and slipped capital femoral
CC       epiphysis. {ECO:0000269|PubMed:22870295,
CC       ECO:0000269|PubMed:23827346, ECO:0000269|PubMed:24057292,
CC       ECO:0000269|PubMed:24259409}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Short stature with non-specific skeletal abnormalities
CC       (SNSK) [MIM:616255]: A condition characterized by short stature,
CC       defined as a height less than 2 SD below normal, and no endocrine
CC       abnormalities. {ECO:0000269|PubMed:24001744,
CC       ECO:0000269|PubMed:24471569}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the adenylyl cyclase class-4/guanylyl
CC       cyclase family. {ECO:0000255|PROSITE-ProRule:PRU00099}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB005647; BAA81737.1; -; Genomic_DNA.
DR   EMBL; AJ005282; CAA06466.1; -; mRNA.
DR   EMBL; AL133410; CAI10987.1; -; Genomic_DNA.
DR   EMBL; EU326311; ACA05920.1; -; Genomic_DNA.
DR   EMBL; EU326311; ACA05921.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58338.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58337.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58339.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58340.1; -; Genomic_DNA.
DR   EMBL; BC023017; AAH23017.1; -; mRNA.
DR   CCDS; CCDS6590.1; -. [P20594-1]
DR   PIR; S05514; OYHUBR.
DR   RefSeq; NP_003986.2; NM_003995.3. [P20594-1]
DR   UniGene; Hs.78518; -.
DR   ProteinModelPortal; P20594; -.
DR   SMR; P20594; -.
DR   BioGrid; 110942; 4.
DR   IntAct; P20594; 2.
DR   STRING; 9606.ENSP00000341083; -.
DR   ChEMBL; CHEMBL2111337; -.
DR   DrugBank; DB01613; Erythrityl Tetranitrate.
DR   DrugBank; DB04899; Nesiritide.
DR   GuidetoPHARMACOLOGY; 1748; -.
DR   TCDB; 8.A.85.1.2; the guanylate cyclase (gc) family.
DR   iPTMnet; P20594; -.
DR   PhosphoSitePlus; P20594; -.
DR   BioMuta; NPR2; -.
DR   DMDM; 113916; -.
DR   EPD; P20594; -.
DR   MaxQB; P20594; -.
DR   PaxDb; P20594; -.
DR   PeptideAtlas; P20594; -.
DR   PRIDE; P20594; -.
DR   DNASU; 4882; -.
DR   Ensembl; ENST00000342694; ENSP00000341083; ENSG00000159899. [P20594-1]
DR   GeneID; 4882; -.
DR   KEGG; hsa:4882; -.
DR   UCSC; uc003zyd.4; human. [P20594-1]
DR   CTD; 4882; -.
DR   DisGeNET; 4882; -.
DR   GeneCards; NPR2; -.
DR   H-InvDB; HIX0034787; -.
DR   HGNC; HGNC:7944; NPR2.
DR   MalaCards; NPR2; -.
DR   MIM; 108961; gene.
DR   MIM; 602875; phenotype.
DR   MIM; 615923; phenotype.
DR   MIM; 616255; phenotype.
DR   neXtProt; NX_P20594; -.
DR   OpenTargets; ENSG00000159899; -.
DR   Orphanet; 40; Acromesomelic dysplasia, Maroteaux type.
DR   Orphanet; 329191; Tall stature - scoliosis - macrodactyly of the great toes.
DR   PharmGKB; PA257; -.
DR   eggNOG; KOG1023; Eukaryota.
DR   eggNOG; COG2114; LUCA.
DR   GeneTree; ENSGT00760000118959; -.
DR   HOVERGEN; HBG051862; -.
DR   InParanoid; P20594; -.
DR   KO; K12324; -.
DR   OMA; HQVYTRE; -.
DR   OrthoDB; EOG091G02QS; -.
DR   PhylomeDB; P20594; -.
DR   TreeFam; TF106338; -.
DR   BRENDA; 4.6.1.2; 2681.
DR   Reactome; R-HSA-5578768; Physiological factors.
DR   ChiTaRS; NPR2; human.
DR   GeneWiki; NPR2; -.
DR   GenomeRNAi; 4882; -.
DR   PRO; PR:P20594; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000159899; -.
DR   CleanEx; HS_NPR2; -.
DR   ExpressionAtlas; P20594; baseline and differential.
DR   Genevisible; P20594; HS.
DR   GO; GO:0008074; C:guanylate cyclase complex, soluble; IBA:GO_Central.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:Ensembl.
DR   GO; GO:0005525; F:GTP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004383; F:guanylate cyclase activity; IDA:UniProtKB.
DR   GO; GO:0042562; F:hormone binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR   GO; GO:0016941; F:natriuretic peptide receptor activity; IDA:UniProtKB.
DR   GO; GO:0017046; F:peptide hormone binding; IPI:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IEA:InterPro.
DR   GO; GO:0060348; P:bone development; IEA:Ensembl.
DR   GO; GO:0097011; P:cellular response to granulocyte macrophage colony-stimulating factor stimulus; IEP:UniProtKB.
DR   GO; GO:0006182; P:cGMP biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro.
DR   GO; GO:0051447; P:negative regulation of meiotic cell cycle; IEA:Ensembl.
DR   GO; GO:1900194; P:negative regulation of oocyte maturation; IEA:Ensembl.
DR   GO; GO:0001503; P:ossification; IEA:UniProtKB-KW.
DR   GO; GO:0007168; P:receptor guanylyl cyclase signaling pathway; IDA:UniProtKB.
DR   GO; GO:0008217; P:regulation of blood pressure; TAS:ProtInc.
DR   GO; GO:1903779; P:regulation of cardiac conduction; TAS:Reactome.
DR   GO; GO:0044702; P:single organism reproductive process; IEA:Ensembl.
DR   Gene3D; 3.30.70.1230; -; 1.
DR   InterPro; IPR001054; A/G_cyclase.
DR   InterPro; IPR018297; A/G_cyclase_CS.
DR   InterPro; IPR001828; ANF_lig-bd_rcpt.
DR   InterPro; IPR001170; ANPR/GUC.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR029787; Nucleotide_cyclase.
DR   InterPro; IPR028082; Peripla_BP_I.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   Pfam; PF01094; ANF_receptor; 1.
DR   Pfam; PF00211; Guanylate_cyc; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PRINTS; PR00255; NATPEPTIDER.
DR   SMART; SM00044; CYCc; 1.
DR   SUPFAM; SSF53822; SSF53822; 1.
DR   SUPFAM; SSF55073; SSF55073; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00458; ANF_RECEPTORS; 1.
DR   PROSITE; PS00452; GUANYLATE_CYCLASE_1; 1.
DR   PROSITE; PS50125; GUANYLATE_CYCLASE_2; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; cGMP biosynthesis;
KW   Complete proteome; Disease mutation; Disulfide bond; Dwarfism;
KW   Glycoprotein; GTP-binding; Lyase; Membrane; Nucleotide-binding;
KW   Osteogenesis; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL        1     22       {ECO:0000255}.
FT   CHAIN        23   1047       Atrial natriuretic peptide receptor 2.
FT                                /FTId=PRO_0000012364.
FT   TOPO_DOM     23    458       Extracellular. {ECO:0000255}.
FT   TRANSMEM    459    478       Helical. {ECO:0000255}.
FT   TOPO_DOM    479   1047       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      513    786       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      861    991       Guanylate cyclase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00099}.
FT   MOD_RES     513    513       Phosphoserine.
FT                                {ECO:0000269|PubMed:20977274}.
FT   MOD_RES     516    516       Phosphothreonine.
FT                                {ECO:0000269|PubMed:20977274}.
FT   MOD_RES     518    518       Phosphoserine.
FT                                {ECO:0000269|PubMed:20977274}.
FT   MOD_RES     522    522       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P16066}.
FT   MOD_RES     523    523       Phosphoserine.
FT                                {ECO:0000269|PubMed:20977274}.
FT   MOD_RES     526    526       Phosphoserine.
FT                                {ECO:0000269|PubMed:20977274}.
FT   MOD_RES     529    529       Phosphothreonine.
FT                                {ECO:0000269|PubMed:20977274}.
FT   CARBOHYD     24     24       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD     35     35       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    161    161       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    195    195       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    244    244       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    277    277       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    349    349       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     75    101       {ECO:0000250}.
FT   DISULFID    439    439       Interchain. {ECO:0000305}.
FT   DISULFID    448    448       Interchain. {ECO:0000305}.
FT   VAR_SEQ     964   1047       PVCAGVVGLKMPRYCLFGDTVNTASRMESNGQALKIHVSST
FT                                TKDALDELGCFQLELRGDVEMKGKGKMRTYWLLGERKGPPG
FT                                LL -> KADSHSSPSLHLSQTLPTCFFSKGQSVLGLLA
FT                                (in isoform Short).
FT                                {ECO:0000303|PubMed:10073597}.
FT                                /FTId=VSP_001810.
FT   VARIANT      32     32       P -> T (in AMDM; dbSNP:rs28931581).
FT                                {ECO:0000269|PubMed:15146390}.
FT                                /FTId=VAR_022583.
FT   VARIANT      76     76       S -> P (in SNSK; loss of C-type
FT                                natriuretic peptide-induced signaling;
FT                                dominant negative effect; loss of
FT                                localization to the plasma membrane;
FT                                dbSNP:rs796065355).
FT                                {ECO:0000269|PubMed:24001744}.
FT                                /FTId=VAR_074678.
FT   VARIANT     110    110       R -> C (in SNSK; loss of C-type
FT                                natriuretic peptide-induced signaling;
FT                                dominant negative effect; retained in the
FT                                endoplasmic reticulum;
FT                                dbSNP:rs758478717).
FT                                {ECO:0000269|PubMed:24471569}.
FT                                /FTId=VAR_074679.
FT   VARIANT     115    115       W -> G (in AMDM; markedly deficient
FT                                activity; dbSNP:rs28931582).
FT                                {ECO:0000269|PubMed:15146390}.
FT                                /FTId=VAR_022584.
FT   VARIANT     176    176       D -> E (in AMDM; dbSNP:rs28929479).
FT                                {ECO:0000269|PubMed:15146390}.
FT                                /FTId=VAR_022585.
FT   VARIANT     187    187       V -> I (rare polymorphism; does not
FT                                affect C-type natriuretic peptide-induced
FT                                signaling; dbSNP:rs768423636).
FT                                {ECO:0000269|PubMed:24471569}.
FT                                /FTId=VAR_074680.
FT   VARIANT     232    232       M -> I (in dbSNP:rs55747238).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042219.
FT   VARIANT     263    263       R -> P (in SNSK; loss of C-type
FT                                natriuretic peptide-induced signaling;
FT                                dominant negative effect; loss of
FT                                localization to the plasma membrane).
FT                                {ECO:0000269|PubMed:24001744}.
FT                                /FTId=VAR_074681.
FT   VARIANT     297    297       T -> M (in AMDM; markedly deficient
FT                                activity). {ECO:0000269|PubMed:15146390}.
FT                                /FTId=VAR_022586.
FT   VARIANT     338    338       Y -> C (in AMDM).
FT                                {ECO:0000269|PubMed:15146390}.
FT                                /FTId=VAR_022587.
FT   VARIANT     409    409       A -> T (in AMDM).
FT                                {ECO:0000269|PubMed:15146390}.
FT                                /FTId=VAR_022588.
FT   VARIANT     413    413       G -> E (in AMDM; markedly deficient
FT                                activity). {ECO:0000269|PubMed:15146390}.
FT                                /FTId=VAR_022589.
FT   VARIANT     417    417       Q -> E (in SNSK; loss of C-type
FT                                natriuretic peptide-induced signaling;
FT                                dominant negative effect; no effect on
FT                                cell surface expression;
FT                                dbSNP:rs796065356).
FT                                {ECO:0000269|PubMed:24471569}.
FT                                /FTId=VAR_074682.
FT   VARIANT     488    488       A -> P (in ECDM; mutant and wild-type
FT                                alleles have similar expression levels;
FT                                the mutation results in increased
FT                                guanylate cyclase activity;
FT                                dbSNP:rs587777597).
FT                                {ECO:0000269|PubMed:24259409}.
FT                                /FTId=VAR_071875.
FT   VARIANT     655    655       R -> C (in ECDM; the mutation results in
FT                                increased guanylate cyclase activity;
FT                                dbSNP:rs587777596).
FT                                {ECO:0000269|PubMed:24057292}.
FT                                /FTId=VAR_071876.
FT   VARIANT     658    658       L -> F (in AMDM; no effect on subcellular
FT                                location; changed glycosylation; no
FT                                effect on C-type natriuretic peptide
FT                                binding; decreased guanylate cyclase
FT                                activity; loss of natriuretic peptide
FT                                receptor activity; dominant negative
FT                                effect). {ECO:0000269|PubMed:17652215,
FT                                ECO:0000269|PubMed:26980729}.
FT                                /FTId=VAR_076481.
FT   VARIANT     708    708       Y -> C (in AMDM; no effect on subcellular
FT                                location; changed glycosylation; no
FT                                effect on C-type natriuretic peptide
FT                                binding; decreased guanylate cyclase
FT                                activity). {ECO:0000269|PubMed:15146390,
FT                                ECO:0000269|PubMed:26980729}.
FT                                /FTId=VAR_022590.
FT   VARIANT     771    771       Q -> E (in dbSNP:rs5816).
FT                                /FTId=VAR_011968.
FT   VARIANT     776    776       R -> W (in AMDM; no effect on subcellular
FT                                location; changed glycosylation; no
FT                                effect on C-type natriuretic peptide
FT                                binding; decreased guanylate cyclase
FT                                activity). {ECO:0000269|PubMed:15146390,
FT                                ECO:0000269|PubMed:26980729}.
FT                                /FTId=VAR_022591.
FT   VARIANT     819    819       R -> C (in SNSK; loss of C-type
FT                                natriuretic peptide-induced signaling;
FT                                dominant negative effect; no effect on
FT                                cell surface expression;
FT                                dbSNP:rs766256429).
FT                                {ECO:0000269|PubMed:24001744}.
FT                                /FTId=VAR_074683.
FT   VARIANT     882    882       V -> I (in dbSNP:rs55700371).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042220.
FT   VARIANT     882    882       V -> M (in ECDM; the mutation results in
FT                                higher guanylate cyclase activity; causes
FT                                a 15-fold increase in basal Vmax; has
FT                                higher affinity for GTP than wild-type in
FT                                the presence of NPPC; might lead to a
FT                                structural change that locks the enzyme
FT                                in a conformation mimicking the ATP-bound
FT                                state). {ECO:0000269|PubMed:22870295,
FT                                ECO:0000269|PubMed:23827346}.
FT                                /FTId=VAR_071877.
FT   VARIANT     957    957       R -> C (in AMDM; dbSNP:rs370158184).
FT                                {ECO:0000269|PubMed:15146390}.
FT                                /FTId=VAR_022592.
FT   VARIANT     959    959       G -> A (in AMDM; no effect on subcellular
FT                                location; changed glycosylation; no
FT                                effect on C-type natriuretic peptide
FT                                binding; decreased guanylate cyclase
FT                                activity). {ECO:0000269|PubMed:15146390,
FT                                ECO:0000269|PubMed:26980729}.
FT                                /FTId=VAR_022593.
FT   MUTAGEN      24     24       N->D,Q: Decreased glycosylation.
FT                                Decreased guanylate cyclase activity.
FT                                {ECO:0000269|PubMed:26980729}.
FT   CONFLICT    755    755       T -> S (in Ref. 2; BAA81737).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1047 AA;  117022 MW;  817FB74D6B31F7EF CRC64;
     MALPSLLLLV AALAGGVRPP GARNLTLAVV LPEHNLSYAW AWPRVGPAVA LAVEALGRAL
     PVDLRFVSSE LEGACSEYLA PLSAVDLKLY HDPDLLLGPG CVYPAASVAR FASHWRLPLL
     TAGAVASGFS AKNDHYRTLV RTGPSAPKLG EFVVTLHGHF NWTARAALLY LDARTDDRPH
     YFTIEGVFEA LQGSNLSVQH QVYAREPGGP EQATHFIRAN GRIVYICGPL EMLHEILLQA
     QRENLTNGDY VFFYLDVFGE SLRAGPTRAT GRPWQDNRTR EQAQALREAF QTVLVITYRE
     PPNPEYQEFQ NRLLIRARED FGVELGPSLM NLIAGCFYDG ILLYAEVLNE TIQEGGTRED
     GLRIVEKMQG RRYHGVTGLV VMDKNNDRET DFVLWAMGDL DSGDFQPAAH YSGAEKQIWW
     TGRPIPWVKG APPSDNPPCA FDLDDPSCDK TPLSTLAIVA LGTGITFIMF GVSSFLIFRK
     LMLEKELASM LWRIRWEELQ FGNSERYHKG AGSRLTLSLR GSSYGSLMTA HGKYQIFANT
     GHFKGNVVAI KHVNKKRIEL TRQVLFELKH MRDVQFNHLT RFIGACIDPP NICIVTEYCP
     RGSLQDILEN DSINLDWMFR YSLINDLVKG MAFLHNSIIS SHGSLKSSNC VVDSRFVLKI
     TDYGLASFRS TAEPDDSHAL YAKKLWTAPE LLSGNPLPTT GMQKADVYSF GIILQEIALR
     SGPFYLEGLD LSPKEIVQKV RNGQRPYFRP SIDRTQLNEE LVLLMERCWA QDPAERPDFG
     QIKGFIRRFN KEGGTSILDN LLLRMEQYAN NLEKLVEERT QAYLEEKRKA EALLYQILPH
     SVAEQLKRGE TVQAEAFDSV TIYFSDIVGF TALSAESTPM QVVTLLNDLY TCFDAIIDNF
     DVYKVETIGD AYMVVSGLPG RNGQRHAPEI ARMALALLDA VSSFRIRHRP HDQLRLRIGV
     HTGPVCAGVV GLKMPRYCLF GDTVNTASRM ESNGQALKIH VSSTTKDALD ELGCFQLELR
     GDVEMKGKGK MRTYWLLGER KGPPGLL
//
